Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.54 |
| ▸ | FPR2 | P25090 | 1/20 | 0.53 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | PPARG | P37231 | 1/20 | 0.48 |
| ▸ | PPARA | Q07869 | 1/20 | 0.48 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.47 |
| ▸ | MMP2 | P08253 | 1/20 | 0.47 |
| ▸ | MMP9 | P14780 | 1/20 | 0.47 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.46 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.46 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3156701 | 1.00 | ALDH1A1 (0.54) | ALDH1A1ALOX15FPR2CAPN1KMT2A | |
| SCHEMBL1702385 | 0.87 | FPR2 (0.55) | ALDH1A1ALOX15FPR2KMT2APPARG | |
| SCHEMBL1395877 | 0.84 | FPR2 (0.67) | ALDH1A1ALOX15FPR2KMT2APPARG | |
| SCHEMBL1702272 | 0.83 | PPARG (0.47) | ALDH1A1ALOX15PPARGPPARAKEAP1 | |
| SCHEMBL5080118 | 0.82 | CAPN1 (0.40) | ALDH1A1ALOX15FPR2CAPN1KMT2A | |
| SCHEMBL5215651 | 0.78 | ALDH1A1 (0.67) | ALDH1A1ALOX15FPR2KMT2AGAA | |
| SCHEMBL7390734 | 0.78 | ALDH1A1 (0.67) | ALDH1A1ALOX15FPR2KMT2AGAA | |
| SCHEMBL2003954 | 0.78 | ITGA4 (0.41) | ALDH1A1ALOX15FPR2CAPN1KMT2A | |
| SCHEMBL157547 | 0.76 | MME (0.61) | NPSR1MMP2MMP9 | |
| SCHEMBL20232564 | 0.76 | HSD17B10 (0.46) | POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200399311-A1 | NOVEL PEPTIDE BASED PCSK9 VACCINE | ZYDUS LIFESCIENCES LIMITED (IN) | 2020-12-24 | — | — | US | claimed |
| EP-3609532-A1 | NOVEL PEPTIDE BASED PCSK9 VACCINE | Cadila Healthcare Limited (IN) | 2020-02-19 | — | — | EP | claimed |
| WO-2018189705-A1 | NOVEL PEPTIDE BASED PCSK9 VACCINE | CADILA HEALTHCARE LIMITED (IN) | 2018-10-18 | — | — | WO | claimed |
| US-8383581-B2 | Short-chain peptides as parathyroid hormone (PTH) receptor agonist | CADILA HEALTHCARE LIMITED (IN) | 2013-02-26 | — | — | US | claimed |
| US-20120264685-A1 | SHORT CHAIN PEPTIDOMIMETICS BASED ORALLY ACTIVE GLP 1 AGONIST AND GLUCAGON RECEPTOR ANTAGONIST | CADILA HEALTHCARE LIMITED (IN) | 2012-10-18 | — | — | US | claimed |
| WO-2012120532-A2 | CYCLIC SHORT CHAIN PEPTIDES | CADILA HEALTHCARE LIMITED (IN) | 2012-09-13 | — | — | WO | claimed |
| EP-2491054-A2 | SHORT CHAIN PEPTIDOMIMETICS BASED ORALLY ACTIVE GLP-1 AGONIST AND GLUCAGON RECEPTOR ANTAGONIST | Cadila Healthcare Limited (IN) | 2012-08-29 | — | — | EP | claimed |
| US-20120108496-A1 | SHORT-CHAIN PEPTIDES AS PARATHYROID HORMONE (PTH) RECEPTOR AGONIST | CADILA HEALTHCARE LIMITED (IN) | 2012-05-03 | — | — | US | claimed |
| EP-2421893-A2 | SHORT-CHAIN PEPTIDES AS PARATHYROID HORMONE (PTH) RECEPTOR AGONIST | Cadila Healthcare Limited (IN) | 2012-02-29 | — | — | EP | claimed |
| WO-2011048614-A2 | SHORT CHAIN PEPTIDOMIMETICS BASED ORALLY ACTIVE GLP-1 AGONIST AND GLUCAGON RECEPTOR ANTAGONIST | CADILA HEALTHCARE LIMITED (IN) | 2011-04-28 | — | — | WO | claimed |
| WO-2010128521-A2 | SHORT-CHAIN PEPTIDES AS PARATHYROID HORMONE (PTH) RECEPTOR AGONIST | CADILA HEALTHCARE LIMITED (IN) | 2010-11-11 | — | — | WO | claimed |
| US-11325945-B2 | Peptide based PCSK9 vaccine | CADILA HEALTHCARE LIMITED (IN) | 2022-05-10 | — | — | US | disclosed |
| US-20200399311-A1 | NOVEL PEPTIDE BASED PCSK9 VACCINE | ZYDUS LIFESCIENCES LIMITED (IN) | 2020-12-24 | — | — | US | disclosed |
| EP-3609532-A1 | NOVEL PEPTIDE BASED PCSK9 VACCINE | Cadila Healthcare Limited (IN) | 2020-02-19 | — | — | EP | disclosed |
| WO-2018189705-A1 | NOVEL PEPTIDE BASED PCSK9 VACCINE | CADILA HEALTHCARE LIMITED (IN) | 2018-10-18 | — | — | WO | disclosed |
| US-20120021972-A1 | PEPTIDOMIMETICS WITH GLUCAGON ANTAGONISTIC AND GLP 1 AGONISTIC ACTIVITIES | CADILA HEALTHCARE LIMITED (IN) | 2012-01-26 | — | — | US | disclosed |
| WO-2011048614-A2 | SHORT CHAIN PEPTIDOMIMETICS BASED ORALLY ACTIVE GLP-1 AGONIST AND GLUCAGON RECEPTOR ANTAGONIST | CADILA HEALTHCARE LIMITED (IN) | 2011-04-28 | — | — | WO | disclosed |
| WO-2010128521-A2 | SHORT-CHAIN PEPTIDES AS PARATHYROID HORMONE (PTH) RECEPTOR AGONIST | CADILA HEALTHCARE LIMITED (IN) | 2010-11-11 | — | — | WO | disclosed |
| EP-2231701-A2 | PEPTIDOMIMETICS WITH GLUCAGON ANTAGONISTIC AND GLP-1 AGONISTIC ACTIVITIES | Cadila Healthcare Limited (IN) | 2010-09-29 | — | — | EP | disclosed |
| WO-2009125424-A2 | PEPTIDOMIMETICS WITH GLUCAGON ANTAGONISTIC AND GLP-1 AGONISTIC ACTIVITIES | CADILA HEALTHCARE LIMITED (IN) | 2009-10-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108496-A1 | SHORT-CHAIN PEPTIDES AS PARATHYROID HORMONE (PTH) RECEPTOR AGONIST | PTH1R, GIPR, PTMS | ALDH1A1 3467/4885ALOX15 325/4885FPR2 563/4885 |
| US-11325945-B2 | Peptide based PCSK9 vaccine | PCSK9, PCSK7, PCSK6 | ALDH1A1 4756/4885ALOX15 147/4885FPR2 265/4885 |
| US-20120264685-A1 | SHORT CHAIN PEPTIDOMIMETICS BASED ORALLY ACTIVE GLP 1 AGONIST AND GLUCAGON RECEPTOR ANTAGONIST | GIPR, GLP1R, DPP4 | ALDH1A1 2704/4885ALOX15 1790/4885FPR2 2288/4885 |
| US-20200399311-A1 | NOVEL PEPTIDE BASED PCSK9 VACCINE | PCSK9, PCSK7, PCSK6 | ALDH1A1 4683/4885ALOX15 202/4885FPR2 392/4885 |
| US-20120021972-A1 | PEPTIDOMIMETICS WITH GLUCAGON ANTAGONISTIC AND GLP 1 AGONISTIC ACTIVITIES | GLP1R, GPR119, GIPR | ALDH1A1 3147/4885ALOX15 3473/4885FPR2 414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.